BMP-7: dosing and use context
> Updated:
Calculate the BMP-7 (OP-1) dose
Enter your dose and diluent volume for BMP-7 (OP-1) — the calculator will do the rest.
Human dosing
| Period / condition | Dose | Escalation |
|---|---|---|
| Phase 1, knee (intra-articular, single dose) | 0.1 mg | Starting dose |
| Phase 1, higher level (intra-articular, single dose) | 0.3 mg | Increase if needed |
| Surgical implant (OP-1, on collagen, local) | 3.5 mg | Maximum in this schedule |
| Preclinical systemic reference (animal) | 30 mcg/kg, twice weekly | , |
Practical dosage and effect notes
In the phase 1 trial by Hunter and colleagues (BMC Musculoskeletal Disorders, 2010), four single intra-articular doses of BMP-7 were tested in knee osteoarthritis: 0.03, 0.1, 0.3, and 1 mg, 8 participants per cohort (3:1 active to placebo). No dose-limiting toxicity appeared at any level. Notably, the 0.1 mg and 0.3 mg doses showed a trend toward greater symptomatic improvement than placebo, while the 1 mg dose performed worse and came with more frequent injection-site pain.
That is a bell-shaped dose-response curve, where more is not better. It is why 0.1 mg and 0.3 mg in the table above are not an arbitrary pick but the upper edge of the effective phase 1 range, while the higher 1 mg level underperformed in the same trial. By week 12, both groups, placebo included, improved on pain by roughly 20%, which is worth keeping in mind when weighing the drug's own effect.
This is background for planning a research protocol, not a medical recommendation and not instructions for self-administration.
Research protocols
BMP-7: reference regimens
Controlled data on this compound are limited.
BMP-7 (recombinant bone morphogenetic protein-7) is used in studies not as a routine injectable peptide but locally: by intra-articular injection or surgical implantation on a collagen carrier. No systemic (subcutaneous) human regimen is established.
BMP-7 dosing in clinical studies means a single image-guided intra-articular injection, not a course of repeated doses: no repeat-dose human regimen has been described in the literature.
More scientific background in the BMP-7 (OP-1) monograph
Notes and safety
- • BMP-7 (OP-1) is a research peptide. Human safety and efficacy data are limited.
- • The regimens shown are based on publications and research protocols, not clinical recommendations.
- • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
- • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
- • This information is for educational purposes and is not medical advice.
BMP-7 (OP-1)